Text size A A

News

Date Title and Summary Additional Formats
Toggle Summary AGTC to Present at Upcoming Gene Therapy Conferences
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 29, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases, today
View HTML
Toggle Summary AGTC to Present at Upcoming Conferences
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases, today
View HTML
Toggle Summary AGTC Announces Financial Results and Business Update for the Quarter and Fiscal Year Ended June 30, 2017
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare
View HTML
Toggle Summary AGTC Appoints Matthew Feinsod, M.D. as Interim Chief Medical Officer
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the
View HTML
Toggle Summary AGTC to Host Fourth Quarter and Fiscal Year Financial Results Conference Call and Webcast on September 13, 2017
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases, today
View HTML
Toggle Summary AGTC and the Foundation Fighting Blindness Announce Partnership Agreement
AGTC Grant Will Support FFB's Patient Registry and Local Programs
View HTML
Toggle Summary AGTC Files Investigational New Drug Application for the Treatment of X-linked Retinitis Pigmentosa Caused by Mutations in the RPGR Gene
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC to Present at the Wedbush PacGrow Healthcare Conference on August 16, 2017
AGTC to Present at the Wedbush PacGrow Healthcare Conference on August 16, 2017 GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation ( AGTC ), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based
View HTML
Toggle Summary Research Published in Molecular Therapy Identifies Optimal Gene-based Therapeutic Construct for X-Linked Retinitis Pigmentosa
Preclinical research led by scientists from the University of Pennsylvania demonstrates effective delivery and expression of functional gene sequences, positive effects on retinal structure and function, and improved visual navigation in animal models
View HTML
Toggle Summary AGTC Announces U.S. FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Visionary science for life changing cures.